The Average price target is noted at $99.45, this average price is calculated and based on coming up with go through the consensus of analysts and stock’s current price is placed at $95.65. Following the sale, the executive vice president now directly owns 63,122 shares of the company’s stock, valued at $5,492,876.44.
Advertisement
Shares of Gilead Sciences (NASDAQ:GILD) traded down 0.01% during trading on Monday, hitting $79.65.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, July 25th. The ratio dropped, as 90 funds sold all Gilead Sciences, Inc. shares owned while 588 reduced positions.
In an overview of the current analyst recommendations, Buy count is 14 and Overweight is 1 while the number of analysts recommending Sell and Underweight are 0 and 0, respectively. The difference between the expected and actual EPS was $0.06/share, which represents an Earnings surprise of 2%. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. The average volume stands around 10.12 million shares.
ATR value of company was 1.46 and Relative Strength Index (RSI) was 41.19. The disclosure for this sale can be found here. Analyst had a consensus of $3.01. Cypress Wealth Advisors LLC now owns 3,875 shares of the biopharmaceutical company’s stock valued at $356,000 after buying an additional 54 shares during the last quarter.
During last one month it showed the change of -8.10%. LLC raised its stake in shares of Gilead Sciences by 20.8% in the second quarter. Year to Date, the current share price of the stock is below -21.28%. Finally, Mountain Pacific Investment Advisers Inc. Mountain Pacific Investment Advisers Inc. During the same period in the previous year, the firm earned $3.15 earnings per share. On Aug 18, 2015 the shares registered one year high at $117.70 and the one year low of $77.92 was seen on Jun 27, 2016. 1 analyst has suggested “Sell” for the company. The investment management firm now holds a total of 15,363 shares of Gilead Sciences which is valued at $1,222,434.Gilead Sciences makes up approximately 1.01% of Cfo4life’s portfolio. Also, the Hold rating count is 11 as of 42594.
Finally, Oppenheimer Holdings Inc. reaffirmed a “buy” rating and issued a $116.00 price objective (down from $120.00) on shares of Gilead Sciences in a research report on Wednesday, May 4th.
Some buy side analysts are also providing their Analysis on Gilead Sciences, Inc., where 6 analysts have rated the stock as Strong buy, 10 analysts have given a Buy signal, 9 said it’s a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell.
Advertisement
Though Schimmer acknowledges that “GILD’s overall pipeline is rather disappointing”, and recognizes the short-term follies the firm might face, the analyst reiterates an Overweight rating on Gilead with a $108 price target, which represents a almost 36% increase from where the stock is now trading. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The company’s products comprise Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases.
